References
- Heffler S, Smith S, Keehan S, et al. U.S. health spending projections for 2004–2014. Health Aff. (Millwood) 2005;Suppl Web Exclusives: W5.
- Smith C, Cowan C, Heffler S, et al. National health spending in 2004: Recent slowdown led by prescription drug spending. Health Aff. (Millwood) 2006;25(1):186–96.
- Levit K, Smith C, Cowan C, et al. Health spending rebound continues in 2002. Health Aff (Millwood) 2004;23(1):147–59.
- Levit K, Smith C, Cowan C, et al. Inflation spurs health spending in 2000. Health Aff. (Millwood) 2002;21(1):172–81.
- Strunk BC, Ginsburg PB, Cookson JP. Tracking health care costs: Declining growth trend pauses in 2004. Health Aff. (Millwood) 2005;Suppl Web Exclusives: W5.
- Heffler S, Smith S, Keehan S, et al. Health spending projections for 2002–2012. Health Aff. (Millwood) 2003;Suppl Web Exclusives:W3–65.
- Heffler S, Smith S, Keehan S, et al. Health spending projections through 2013. Health Aff. (Millwood) 2004.
- Gabel J, Claxton G, Gil I, et al. Health benefits in 2004: Four years of double-digit premium increases take their toll on coverage. Health Aff. (Millwood) 2004;23(5):200–9.
- Iglehart JK. Medicare and drug pricing. N Engl J Med. 2003;348(16):1590–7.
- Halbert RJ, Zaher C, Wade S, et al. Outpatient cancer drug costs: Changes, drivers, and the future. Cancer. 2002;94(4):1142–50.
- Schrag D. The price tag on progress—chemotherapy for colorectal cancer. N Engl J Med. 2004;351(4):317–9.
- Cunningham D, Humblet Y, Siena S, et al. Cetuximab mono-therapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–45.
- Neuman, PJ. Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. Oxford, N.Y.: Oxford University Press; 2005.